SCHEMBL6133611

SCHEMBL6133611

CCn1nc(-c2sc(C(N)=O)nc2-c2ccccc2)ccc1=O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.44
HSD17B10 Q99714 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 3/20 0.39
TP53 P04637 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
CYP1A2 P05177 1/20 0.38
ADORA2A P29274 1/20 0.38
TSHR P16473 1/20 0.38
ADORA1 P30542 2/20 0.37
ADORA3 P0DMS8 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6133851 0.91 HSD17B10 (0.45) HTTHSD17B10SMN1; SMN2KDM4ETP53
SCHEMBL6133402 0.86 KDM4E (0.41) HTTHSD17B10KDM4ETP53MEN1
SCHEMBL6133966 0.86 HTT (0.52) HTTHSD17B10SMN1; SMN2KDM4EMEN1
SCHEMBL6134015 0.86 KDM4E (0.45) HTTHSD17B10SMN1; SMN2KDM4ETP53
SCHEMBL6133574 0.85 HSD17B10 (0.46) HTTHSD17B10SMN1; SMN2KDM4ETP53
SCHEMBL6133356 0.85 KDM4E (0.51) HTTHSD17B10SMN1; SMN2KDM4EMEN1
SCHEMBL6133994 0.85 ALDH1A1 (0.46) HTTKDM4EADORA2AADORA1POLB
SCHEMBL6134833 0.84 ALDH1A1 (0.51) HTTHSD17B10SMN1; SMN2KDM4EMEN1
SCHEMBL6133518 0.83 USP2 (0.46) HTTHSD17B10SMN1; SMN2TP53PDE4B
SCHEMBL6133425 0.82 RET (0.41) HTTKDM4ETP53KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004134-A1 Thiazole derivative and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004134-A1 Thiazole derivative and pharmaceutical use thereof MC2R, CYP2C9, OXTR HTT 477/4885HSD17B10 391/4885SMN1; SMN2 3135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.